Novel targeted cancer therapies, especially kinase inhibitors, have revolutionized the treatment of many cancers and have dramatically improved the survival of several types of malignancies. Because kinases not only are important in cancer development and progression, but also play a critical role in the cardiovascular (CV) system and metabolic homeostasis, important CV and metabolic sequelae have been associated with several types of kinase inhibitors. This paper reviews the incidences and highlights potential mechanisms of vascular and metabolic perturbations associated with 3 classes of commonly used kinase inhibitors that target the vascular endothelial growth factor signaling pathway, the ABL kinase, and the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin signaling pathway. We propose preventive, screening, monitoring, and management strategies for CV care of patients treated with these novel agents. 
2. Monoclonal antibodies (mAbs) that bind the RTK or its ligand. As a result, they can be further subcategorized into mAbs directed against RTKs to prevent ligand binding (e.g., trastuzumab) or RTK dimerization and activation (e.g., pertuzumab); and mAbs directed against the circulating ligand to prevent it from binding to its receptor (e.g., bevacizumab).
3. Soluble decoy receptors ("ligand traps") bind the ligand, preventing it from binding to its receptor.
Small molecule inhibitors have been especially
attractive for clinical use because they can be taken orally and can target more than 1 kinase, thus proving effective in several types of cancer.
CV ENDPOINTS IN ONCOLOGY TRIALS VERSUS CV TRIALS
As life expectancy increases, many diseases that predominantly affect older individuals will become more prevalent. Advancing age is a risk factor for CV disease, metabolic disorder, and cancer. Importantly, cancer and CV disease also share other common risk factors, such as tobacco use, obesity, and physical inactivity (7) . As a result, cancer patients frequently have CV and metabolic comorbidities. Therefore, in the assessment of new cancer therapies, it becomes essential to distinguish between treatment-induced CV and metabolic adverse effects from treatmentindependent events. A robust and consistent monitoring system with standard definitions for treatment-associated CV and metabolic adverse events is essential during the treatment course. In addition, to definitively determine whether a therapy causes CV disease, appropriate control groups are prerequisites. Li et al. by various oncology groups to characterize adverse vascular events, does not fully reflect adverse events that can occur in the cardiac and cerebral vasculature.
S E P T E M B
However, this term gives very little insight into the specific pathophysiology (e.g., thrombosis vs. atherosclerosis) (9) . To understand the incidence and severity of vascular toxicity in oncology studies, it will be useful to develop definitions for vascular events (VE) that match definitions commonly used in CV clinical trials (10) . In this review, we will use VE to refer to both acute and chronic events related to the peripheral circulation reported in the published oncology data.
METABOLIC TOXICITIES
Hyperglycemia, hypertriglyceridemia, and hypercholesterolemia are listed as metabolic adverse effects in the current version of CTCAE (8). However, elevated low density lipoprotein (LDL), which is more relevant to adverse CV events, is not included. antibodies directed against VEGFR, or small-molecule Table 3 .
Nearly all patients treated with these agents However, these studies were retrospective analyses. "Pre-eclampsia-like" theory. Pre-eclampsia is characterized by HTN, proteinuria, and edema, and it affects up to 5% of pregnancies (35) . Interestingly, this similar paradigm of "pre-eclampsia-like" syndrome has also been described in patients treated with VSP inhibitors (36 Figure 1 . Li et al. in high dose) (41) . In a meta-analysis of 6,779 patients from 23 trials, the RR of all-grade bleeding events associated with sunitinib and sorafenib was 2.0 (95% CI: 1.14 to 3.49; p ¼ 0.015) (42) .
M e c h a n i s m s . ECs play a critical role in maintaining vascular homeostasis. They maintain normal blood vascular tone and viscosity, and prevent abnormal blood clotting and bleeding. VEGF signaling maintains EC integrity through activating survival and antiapoptotic signaling (43) . VEGF also increases the bioavailability of NO and prostacyclin, which, although best known as vasodilators, also have several vascular protective effects, including antiplatelet activities. Therefore, VEGF inhibition can alter the vascular hemostatic balance, interfere with the regenerative capacity of ECs, and cause defects of the endothelial layer that expose the underlying matrix, leading to both thrombosis and hemorrhage (44) . An intriguing alternative hypothesis is that VSP inhibitors can form immune complexes that activate platelets and induce thrombosis (45, 46) .
C a r d i o -o n c o l o g y c o n s i d e r a t i o n s . Due to the presence of both thrombotic and hemorrhagic events,
it is a clinical dilemma as to whether antiplatelets or anticoagulants should be used to prevent ATE or VTE The PI3K/AKT/mTOR pathway can modulate the insulin-signaling pathway (93) . PI3K knockout mice display hyperinsulinemia, insulin resistance, and glucose intolerance (94) . In a mouse model of type 2 diabetes, mTOR inhibition increased insulin For this reason, patients with diabetes and ischemic heart disease were often excluded from clinical trials (97); data on the specific incidence and spectrum of metabolic toxicities during treatment with PI3K/AKT/mTOR pathway inhibitors are therefore incomplete. Still, a high incidence of unfavorable metabolic adverse effects was observed to be associated with these agents. In a phase III trial evaluating everolimus in metastatic renal cell carcinoma (mRCC), the incidences of hypertriglyceridemia, hypercholesterolemia, and hyperglycemia were 71%, 76%, and 50%, respectively, which were significantly higher than placebo (30%, 32%, and 23%, respectively) (97) . Similar findings were reported in a clinical trial using temsirolimus in advanced renal cell carcinoma (98) . The most common laboratory abnormalities associated with idelalisib are hyperglycemia and hypertriglyceridemia, which occurred in 54% and 56% of patients, respectively (99) . The frequency of elevation in LDL, an important atherogenic component of cholesterol, is not known because it is not 1 of the adverse events listed in the CTCAE and is not often reported in oncology trials (100).
CARDIO-ONCOLOGY CONSIDERATIONS. Owing to the significant effect of mTOR inhibitors on lipid and glucose metabolism, the Task Force of National Cancer Institute Investigational Drug Steering Committee has proposed specific management of the metabolic side effects of these agents ( Table 5 ) (100).
Because idelalisib was just approved by the FDA in 2014, clinical experience regarding the incidence of 
